glp-1 news today 2025 november 5 Eli Lilly to seek approval of new weight-loss drug this year GLP-1 receptor agonists and next-generation

These agents include: Tirzepatide (Mounjaro, Zepbound though technically a dual GIP/GLP-1 receptor agonist) Semaglutide (Ozempic, Wegovy, Rybelsus) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Exenatide (Byetta, Bydureon) They are widely used in both endocrinology and obesity medicine for managing diabetes, weight, and cardiovascular risk

BPV is also crucial in hypertension development [79]

These effects are generally most noticeable in the first 35 days and often improve as your body adapts

If you have any questions about your specific dosing, please dont hesitate to reach out to our team at Good Hearts Health

Stay Socially Connected Even if youre not eating as much in social situations, dont let that stop you from participating

These medications help reduce appetite and improve blood sugar control, making them a valuable tool for individuals struggling with obesity and diabetes